Amendments to the Claims under 37 C.F.R. § 1.121

Claim 1 (currently amended): A trimeric polypeptide comprising three monomers, wherein each ~~of said~~ monomer[[s]] ~~comprising~~ comprises a ~~specific~~ cytokine binding ~~member capable of binding a trimeric cytokine~~ domain[[,]] and ~~each of said monomers comprising~~ a tetranectin trimerising domain~~, the trimerising domain is derived from tetranectin~~.

Claims 2-17 (cancelled).

Claim 18 (currently amended): The ~~A~~ trimeric polypeptide according to claim 1, wherein the tetranectin trimerising domain ~~derived from tetranectin~~ comprises an amino acid sequence having at least ~~68% amino acid sequence~~ 87% identity with the amino acid sequence of SEQ ID NO:81.

Claim 19 (currently amended): The ~~A~~ trimeric polypeptide according to claim ~~18~~ 1, wherein the tetranectin trimerising domain comprises an amino acid sequence ~~identity is~~ having at least 92% identity with the amino acid sequence of SEQ ID NO:81.

Claim 20 (currently amended): The trimeric polypeptide according to claim 1, wherein the tetranectin trimerising domain ~~derived from tetranectin~~ comprises the amino acid sequence of SEQ ID NO:81.

Claim 21 (currently amended): The trimeric polypeptide according to claim 1, wherein ~~the~~ at least one monomer comprises the amino acid sequence of ~~is TN-2-B (~~SEQ ID NO:106~~), TN-2-C (~~, SEQ ID NO:108~~), or TN-2-D (~~, or SEQ ID NO:107[[)]].

Claim 22 (currently amended): The trimeric polypeptide according to claim 1, further comprising a linker between the ~~specific~~ cytokine binding ~~member~~ domain and the tetranectin trimerising domain.

McDonnell Boehnen Hulbert & Berghoff LLP
300 South Wacker Drive
Chicago, Illinois 60606
312-913-0001

Claim 23 (previously presented): A pharmaceutical composition comprising the trimeric polypeptide according to claim 1.

Claims 24-29 (cancelled).

Claim 30 (previously presented): A method of preparing a pharmaceutical composition comprising combining the trimeric polypeptide according to claim 1 with a pharmaceutically acceptable carrier.

Claims 31-34 (cancelled).

Claim 35 (currently amended): The trimeric polypeptide according to claim 20, wherein the cysteine residue at position number 50 of the amino acid sequence of SEQ ID NO:81 is mutagenized to a serine, threonine, methionine, or any other amino acid residue.

McDonnell Boehnen Hulbert & Berghoff LLP
300 South Wacker Drive
Chicago, Illinois 60606
312-913-0001